REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013
Executive Summary Parkinson s disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer s disease, affecting 1% 2% of individuals ages 65 years worldwide (de Lau and Breteler, 2006; Willis et al., 2010). Parkinson s disease is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, in addition to non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression (WHO, 2006). Age, genetics, sex, and environmental exposure increase the risk of developing Parkinson s disease. Conditions such as depression and anxiety have been identified as comorbidities in Parkinson s disease. This report provides an overview of the risk factors and comorbidities for Parkinson s disease in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). It includes a 10-year epidemiological forecast of diagnosed prevalent cases of Parkinson s disease segmented by sex and age (ages 65 85+ years). In 2012, there were 2,179,414 diagnosed cases of Parkinson s disease in the 8MM, as shown in 8MM, Diagnosed Prevalent Cases of Parkinson s Disease, Ages 65 Years, Both Sexes, N, 2012 and 2022. By 2022, GlobalData epidemiologists forecast there will be 2,893,575 diagnosed cases of Parkinson s disease in the 8MM. The US will have the highest number of cases in 2022, followed by Brazil and Japan. GlobalData epidemiologists calculated the agestandardized prevalence proportion of Parkinson s disease in the 8MM for 2012. Brazil showed the highest age-standardized prevalence of Parkinson s disease in both men and women in the 8MM. 8MM, Diagnosed Prevalent Cases of Parkinson s Disease, Ages 65 Years, Both Sexes, N, 2012 and 2022 Markets 8MM 5EU Japan Brazil UK Spain Italy Germany France US 0 1,000,000 2,000,000 3,000,000 4,000,000 Prevalent Cases of Parkinson's Disease (N) 2022 2012 Source: GlobalData; Barbosa et al., 2006; Benito-León et al., 2003; Morgante et al., 1992; Schrag et al., 2000; Tison et al., 1994; Trenkwalder et al., 1995; USCB, 2012; Willis et al., 2010; Yamawaki et al., 2009. Note: 5EU = France, Germany, Italy, Spain, and UK; 8MM = US, 5EU, Japan, and Brazil The 8MM will be important markets for Parkinson s disease during the next 10 years because these countries have a growing older population. Japan s current and growing elderly population is the strongest contributor and key driver for increases in Parkinson s disease prevalent cases in Japan. With greater advances in accurately detecting and diagnosing Parkinson s disease in addition to creating a globally and nationally recognized Parkinson s disease registry, we can help further improve our epidemiological understanding of this disorder. 2
Table of Contents 1 Table of Contents 1 Table of Contents... 3 1.1 List of Tables... 5 1.2 List of Figures... 5 2 Introduction... 6 2.1 Catalyst... 6 2.2 Related Reports... 6 2.3 Upcoming Reports... 6 3 Epidemiology... 7 3.1 Disease Background... 7 3.2 Risk Factors and Comorbidities... 7 3.2.1 The risk of developing Parkinson s disease progressively increases with age... 8 3.2.2 The risk for Parkinson s disease is increased with Parkinson s disease causing mutations... 9 3.2.3 Men are 1.5 times more likely to develop Parkinson s disease than women, though the difference may be the result of varying exposures to environmental factors... 9 3.2.4 Chemicals, along with exposure to other environmental factors, increase the risk of developing Parkinson s disease... 10 3.2.5 38% of Parkinson s disease cases experienced depression and/or anxiety compared with only 8% of controls... 11 3.3 Global Trends... 11 3.3.1 US... 11 3.3.2 5EU... 12 3
Table of Contents 3.3.3 Japan... 13 3.3.4 Brazil... 13 3.4 Forecast Methodology... 14 3.4.1 Sources Used... 15 3.4.2 Sources Not Used... 18 3.4.3 Forecast Assumptions and Methods... 18 3.5 Epidemiological Forecast of Parkinson s Disease (2012 2022)... 20 3.5.1 Prevalent Cases of Parkinson s Disease... 20 3.5.2 Age-Specific Prevalent Cases of Parkinson s Disease... 21 3.5.3 Sex-Specific Prevalent Cases of Parkinson s Disease... 23 3.5.4 Age-Standardized Prevalence of Parkinson s Disease... 24 3.6 Discussion... 25 3.6.1 Epidemiological Forecast Insight... 25 3.6.2 Limitations of the Analysis... 26 3.6.3 Strengths of the Analysis... 27 4 Appendix... 28 4.1 Bibliography... 28 4.2 About the Authors... 31 4.2.1 Epidemiologists... 31 4.2.2 Reviewers... 31 4.2.3 Global Director of Epidemiology and Health Policy... 33 4.2.4 Global Head of Healthcare... 33 4.3 About GlobalData... 34 4
Table of Contents 4.4 About EpiCast... 34 4.5 Disclaimer... 35 1.1 List of Tables Table 1: Risk Factors and Comorbidities for Parkinson s Disease... 8 Table 2: Sources of Diagnosed Prevalence Data Used in the Epidemiology Forecast... 15 Table 3: 8MM, Diagnosed Prevalent Cases of Parkinson s Disease, Ages 65 Years, Both Sexes, N, Select Years, 2012 2022... 20 Table 4: 8MM, Diagnosed Prevalent Cases of Parkinson s Disease, by Age, N (Row %), 2012... 22 Table 5: 8MM, Diagnosed Prevalent Cases of Parkinson s Disease, by Sex, N (Row %), 2012... 23 1.2 List of Figures Figure 1: 8MM, Age-Adjusted Mortality Rate of Parkinson s Disease, Both Sexes, N, 2011... 14 Figure 2: 8MM, Diagnosed Prevalent Cases of Parkinson s Disease, Ages 65 Years, Both Sexes, N, Select Years, 2012 2022... 21 Figure 3: 8MM, Diagnosed Prevalent Cases of Parkinson s Disease, by Age, N, 2012... 22 Figure 4: 8MM, Diagnosed Prevalent Cases of Parkinson s Disease, by Sex, N, 2012... 24 Figure 5: 8MM, Age-Standardized Prevalence (%) of Parkinson s Disease, 2012... 25 5
Introduction 2 Introduction 2.1 Catalyst Parkinson s disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer s disease, affecting 1% 2% of individuals ages 65 years worldwide (de Lau and Breteler, 2006; Willis et al., 2010). This report provides an overview of the risk factors and comorbidities for Parkinson s disease in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). It includes a 10-year epidemiological forecast of diagnosed prevalent cases of Parkinson s disease segmented by sex and age (ages 65 85+ years). GlobalData epidemiologists expect that the number of diagnosed prevalent cases of Parkinson s disease in the 8MM will increase during the forecast period from 2,179,414 prevalent cases in 2012 to 2,893,575 prevalent cases in 2022. GlobalData s epidemiological analysis is supported by age- and sex-specific prevalence data from country-specific studies published in peer-reviewed journals. 2.3 Upcoming Reports GlobalData (2013). EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection Epidemiology Forecast to 2022, November, 2013, GDHCER041 GlobalData (2013). EpiCast Report: Bladder Cancer Epidemiology Forecast to 2022, November, 2013, GDHCER042 6
Appendix 4.3 About GlobalData GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports and forecasts. Our analysis is supported by a 24/7 client support and analyst team. GlobalData has offices in New York, Boston, London, India and Singapore. 4.4 About EpiCast EpiCast is a series of premier epidemiology reports written and developed by Masters and PhD level epidemiologists. EpiCast Reports are in-depth, high quality, transparent and market-driven, providing expert analysis of epidemiological trends and forecasting of patient populations for major markets. Specifically, the reports identify disease trends over a 10-year forecast period in six to seven major markets (US, France, Germany, Italy, Spain, UK, Japan). Additional countries, such as Canada, Brazil, India and China, are covered in these reports if their markets are highly relevant. 34
Appendix 4.5 Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData. 35